Trial Profile

A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ENMD 2076 (Primary)
Indications Liver cancer
Focus Therapeutic Use
Sponsors CASI Pharmaceuticals

Most Recent Events

04 Sep 2018 Status changed from active, no longer recruiting to completed.
07 Sep 2017 According to a CASI Pharmaceuticals media release, it is anticipated that the data from this study will be submitted to a medical conference for presentation in 2018.
23 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com